Lihua E. Budde

Hematology | Oncology
1500 Duarte Rd
Duarte, CA 91010

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 96 publications

BAFF-R CAR T-cell therapy for relapsed or refractory B-cell lymphomas.

BAFF-R CAR T-cell therapy for relapsed or refractory B-cell lymphomas.

Journal: Lancet (London, England)
Published: May 26, 2026

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Versus-Host Disease and Nonrelapse Mortality After Allogeneic Transplantation.

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Versus-Host Disease and Nonrelapse Mortality After Allogeneic Transplantation.

Journal: Transplantation and cellular therapy
Published: May 01, 2026

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

Journal: Blood advances
Published: May 01, 2026

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.

Journal: Blood advances
Published: May 01, 2026

A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.

A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.

Journal: Journal of hematology & oncology
Published: March 24, 2026

A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.

A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.

Journal: EJHaem
Published: January 26, 2026

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

Journal: American journal of hematology
Published: January 05, 2026

High Incidence of Cytomegalovirus Infection in Patients Receiving Standard of Care CD19- or BCMA-Targeted CAR-T Cell Therapies for Hematologic Malignancies.

High Incidence of Cytomegalovirus Infection in Patients Receiving Standard of Care CD19- or BCMA-Targeted CAR-T Cell Therapies for Hematologic Malignancies.

Journal: Transplantation and cellular therapy
Published: December 08, 2025

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Journal: American journal of hematology
Published: November 21, 2025

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Journal: Blood
Published: November 13, 2025

Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Journal: Leukemia & lymphoma
Published: October 31, 2025

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025
Showing 1-12 of 96

Last Updated: 09/26/2026